Study of genetic and protein changes in idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a diagnosis of idiopathic pulmonary fibrosis
- Get care at the Simmons Center
- Not have another lung illness that could explain your symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a community registry to learn about people affected by pulmonary fibrosis and related lung conditions, including patients, caregivers, and close family. By joining, you help researchers better understand needs and experiences in the real world.
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
This study looks at people with a condition called idiopathic pulmonary fibrosis (IPF), which causes lung scarring. Researchers want to develop a tool to predict how the disease will progress, so they will collect health data over time to see what factors affect outcomes.
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This study looks at how interstitial lung disease (lung scarring) typically progresses over time. It may help researchers understand what to expect and what changes to watch for.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.